Free tool
FAERS Monitor: Xenon Xe 133
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018327 or its brand name (Xenon Xe 133, Xenon Xe-133). Reports on generic versions are filed under their own applications.
Reports
13
Serious
2
15% of reports
Hospitalization
1
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- occupational exposure to product4
- nasal discomfort2
- throat irritation2
- urticaria2
- accidental exposure1
- accidental exposure to product1
- alanine aminotransferase decreased1
- beta 2 microglobulin increased1
- blood alkaline phosphatase increased1
- blood bilirubin decreased1
- blood cholinesterase decreased1
- blood creatine phosphokinase decreased1
- blood phosphorus increased1
- blood potassium decreased1
- cardiac failure1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2024 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| beta 2 microglobulin increased | 1 | 6229.0 | 943.8 | 1,550 |
| blood cholinesterase decreased | 1 | 5932.4 | 899.1 | 1,477 |
| blood creatine phosphokinase decreased | 1 | 4952.8 | 751.1 | 1,233 |
| blood bilirubin decreased | 1 | 2624.9 | 398.6 | 654 |
| alanine aminotransferase decreased | 1 | 2240.0 | 340.3 | 558 |
| occupational exposure to productSignal | 4 | 1007.3 | 445.5 | 3,077 |
| blood phosphorus increased | 1 | 592.8 | 90.1 | 147 |
| nasal discomfort | 2 | 408.3 | 114.1 | 456 |
| accidental exposure | 1 | 388.7 | 59.1 | 96 |
| throat irritation | 2 | 72.1 | 20.2 | 78 |
| blood alkaline phosphatase increased | 1 | 65.2 | 9.9 | 15 |
| blood potassium decreased | 1 | 53.8 | 8.2 | 12 |
| cardiac failure | 1 | 20.2 | 3.1 | 4 |
| urticaria | 2 | 19.3 | 5.4 | 19 |
| accidental exposure to product | 1 | 15.7 | 2.4 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.